<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font20 { font-size : 20; } .font21 { font-size : 21; } .font24 { font-size : 24; } .font25 { font-size : 25; } .font31 { font-size : 31; }</style>
 <body>
  <p>
   <span class="font31">measles </span>
   <span class="font25">vaccination </span>
   <span class="font25">vaccine </span>
   <span class="font24">mumps </span>
   <span class="font24">age </span>
   <span class="font21">vaccinated </span>
   <span class="font21">measles, </span>
   <span class="font21">rubella </span>
   <span class="font20">assay </span>
   <span class="font19">[]. </span>
   <span class="font19">MMR </span>
   <span class="font18">samples </span>
   <span class="font17">antibody </span>
   <span class="font17">cases </span>
   <span class="font17">immunity </span>
   <span class="font17">sample </span>
   <span class="font17">used </span>
   <span class="font17">{border-style </span>
   <span class="font16">results </span>
   <span class="font16">px;} </span>
   <span class="font15">#ffffff;} </span>
   <span class="font15">antigen </span>
   <span class="font15">based </span>
   <span class="font15">data </span>
   <span class="font15">reported </span>
   <span class="font15">values </span>
   <span class="font15">Fig. </span>
   <span class="font15">IgG </span>
   <span class="font15">groups </span>
   <span class="font15">individuals </span>
   <span class="font15">using </span>
   <span class="font15">Measles </span>
   <span class="font14">Hungary </span>
   <span class="font14">anti-measles </span>
   <span class="font14">.collab: </span>
   <span class="font14">strain </span>
   <span class="font14">ELISA </span>
   <span class="font14">available </span>
   <span class="font14">children </span>
   <span class="font14">humoral </span>
   <span class="font14">months </span>
   <span class="font14">negative </span>
   <span class="font13">Hungary, </span>
   <span class="font13">Patients </span>
   <span class="font13">group </span>
   <span class="font13">high </span>
   <span class="font13">immune </span>
   <span class="font13">number </span>
   <span class="font13">recombinant </span>
   <span class="font13">virus </span>
   <span class="font13">years </span>
   <span class="font13">European </span>
   <span class="font13">Negative </span>
   <span class="font13">Positive </span>
   <span class="font13">coating </span>
   <span class="font13">commercial </span>
   <span class="font13">coverage </span>
   <span class="font13">important </span>
   <span class="font13">methods </span>
   <span class="font13">rubella, </span>
   <span class="font13">serum </span>
   <span class="font13">Clinical </span>
   <span class="font13">Control </span>
   <span class="font13">International </span>
   <span class="font13">Introduction </span>
   <span class="font13">case </span>
   <span class="font13">received </span>
   <span class="font13">respectively. </span>
   <span class="font13">seropositivity </span>
   <span class="font13">trivalent </span>
   <span class="font12">Health </span>
   <span class="font12">Rubella </span>
   <span class="font12">Table </span>
   <span class="font12">World </span>
   <span class="font12">antibodies </span>
   <span class="font12">born </span>
   <span class="font12">current </span>
   <span class="font12">herd </span>
   <span class="font12">population </span>
   <span class="font12">population-level </span>
   <span class="font12">positive </span>
   <span class="font12">px; </span>
   <span class="font12">shown </span>
   <span class="font12">{font-family </span>
   <span class="font12">(Fig. </span>
   <span class="font12">Available </span>
   <span class="font12">Considering </span>
   <span class="font12">Disease </span>
   <span class="font12">Hungarian </span>
   <span class="font12">Infectious </span>
   <span class="font12">Organization </span>
   <span class="font12">commercially </span>
   <span class="font12">compared </span>
   <span class="font12">described </span>
   <span class="font12">different </span>
   <span class="font12">dilution </span>
   <span class="font12">font-size </span>
   <span class="font12">immunity. </span>
   <span class="font12">laboratory </span>
   <span class="font12">levels </span>
   <span class="font12">selected </span>
   <span class="font12">significant </span>
   <span class="font12">use </span>
   <span class="font12">vaccines </span>
   <span class="font12">‘three-in-one’ </span>
   <span class="font12">.%, </span>
   <span class="font12">Assay </span>
   <span class="font12">Centre </span>
   <span class="font12">Diseases, </span>
   <span class="font12">EU/EEA </span>
   <span class="font12">Edmonston </span>
   <span class="font12">Figure </span>
   <span class="font12">GSK </span>
   <span class="font12">July </span>
   <span class="font12">Regarding </span>
   <span class="font12">Schwarz </span>
   <span class="font12">Standard </span>
   <span class="font12">University </span>
   <span class="font12">according </span>
   <span class="font12">assays, </span>
   <span class="font12">detection </span>
   <span class="font12">differences </span>
   <span class="font12">dose </span>
   <span class="font12">doses </span>
   <span class="font12">double; </span>
   <span class="font12">estimated </span>
   <span class="font12">immunisation </span>
   <span class="font12">immunocompromised </span>
   <span class="font12">indirect </span>
   <span class="font12">individual </span>
   <span class="font12">kits </span>
   <span class="font12">mean </span>
   <span class="font12">nucleocapsid </span>
   <span class="font12">outbreaks </span>
   <span class="font12">potential </span>
   <span class="font12">precision </span>
   <span class="font12">ratios </span>
   <span class="font12">reminder </span>
   <span class="font12">result </span>
   <span class="font12">series </span>
   <span class="font12">standards </span>
   <span class="font12">titres </span>
   <span class="font12">viral </span>
   <span class="font12">virus, </span>
   <span class="font12">–%, </span>
   <span class="font11">(.%) </span>
   <span class="font11">.–. </span>
   <span class="font11">AUROC </span>
   <span class="font11">Despite </span>
   <span class="font11">Hungary. </span>
   <span class="font11">Measles, </span>
   <span class="font11">Supplementary </span>
   <span class="font11">[], </span>
   <span class="font11">agreement </span>
   <span class="font11">analysis </span>
   <span class="font11">antigen-based </span>
   <span class="font11">assays </span>
   <span class="font11">attenuated </span>
   <span class="font11">blocking </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">calculated </span>
   <span class="font11">cluster </span>
   <span class="font11">confidence </span>
   <span class="font11">considered </span>
   <span class="font11">control </span>
   <span class="font11">curves </span>
   <span class="font11">defined </span>
   <span class="font11">detected </span>
   <span class="font11">early </span>
   <span class="font11">following </span>
   <span class="font11">gaps </span>
   <span class="font11">highest </span>
   <span class="font11">incubation </span>
   <span class="font11">infections </span>
   <span class="font11">introduced </span>
   <span class="font11">level </span>
   <span class="font11">low </span>
   <span class="font11">lowest </span>
   <span class="font11">mumps, </span>
   <span class="font11">obtained </span>
   <span class="font11">old </span>
   <span class="font11">optimal </span>
   <span class="font11">patients </span>
   <span class="font11">performed </span>
   <span class="font11">protein </span>
   <span class="font11">reagent </span>
   <span class="font11">recent </span>
   <span class="font11">recommended </span>
   <span class="font11">risk </span>
   <span class="font11">samples, </span>
   <span class="font11">seronegativity </span>
   <span class="font11">single </span>
   <span class="font11">solid; </span>
   <span class="font11">test </span>
   <span class="font11">tests </span>
   <span class="font11">times </span>
   <span class="font11">vaccination. </span>
   <span class="font11">validated </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font11">µg/ml </span>
   <span class="font11">‘target’ </span>
   <span class="font11">(), </span>
   <span class="font11">(Supplementary </span>
   <span class="font11">(and </span>
   <span class="font11">(e.g. </span>
   <span class="font11">Based </span>
   <span class="font11">Bland–Altman </span>
   <span class="font11">Comparison </span>
   <span class="font11">Cut-off </span>
   <span class="font11">February </span>
   <span class="font11">Fraction </span>
   <span class="font11">HIT </span>
   <span class="font11">Immunolab, </span>
   <span class="font11">Lancet, </span>
   <span class="font11">Medicine, </span>
   <span class="font11">Mumps </span>
   <span class="font11">PRIORIX </span>
   <span class="font11">Sample </span>
   <span class="font11">Siemens </span>
   <span class="font11">Ukraine </span>
   <span class="font11">Vaccination </span>
   <span class="font11">Youden's </span>
   <span class="font11">administered </span>
   <span class="font11">affected </span>
   <span class="font11">age-specific </span>
   <span class="font11">anti-measles, </span>
   <span class="font11">bold </span>
   <span class="font11">certain </span>
   <span class="font11">characteristics </span>
   <span class="font11">coatings </span>
   <span class="font11">coatings, </span>
   <span class="font11">countries </span>
   <span class="font11">courier; </span>
   <span class="font11">dates </span>
   <span class="font11">development </span>
   <span class="font11">effective </span>
   <span class="font11">em; </span>
   <span class="font11">entire </span>
   <span class="font11">epidemics </span>
   <span class="font11">epidemics, </span>
   <span class="font11">estimates </span>
   <span class="font11">evaluation </span>
   <span class="font11">generally </span>
   <span class="font11">in-house </span>
   <span class="font11">including </span>
   <span class="font11">infection </span>
   <span class="font11">measurement </span>
   <span class="font11">monovalent </span>
   <span class="font11">months, </span>
   <span class="font11">persons </span>
   <span class="font11">previous </span>
   <span class="font11">protection </span>
   <span class="font11">pt;} </span>
   <span class="font11">ratio </span>
   <span class="font11">responses </span>
   <span class="font11">s.d. </span>
   <span class="font11">schedules </span>
   <span class="font11">serological </span>
   <span class="font11">statistically </span>
   <span class="font11">threshold </span>
   <span class="font11">unvaccinated </span>
   <span class="font11">vaccine. </span>
   <span class="font11">values, </span>
   <span class="font11">values: </span>
   <span class="font11">virus-based </span>
   <span class="font11">virus-specific </span>
   <span class="font11">vs. </span>
   <span class="font11">µg/mL, </span>
   <span class="font11">–%) </span>
   <span class="font11">‘control’ </span>
  </p>
 </body>
</html>
